INTECH Investment Management’s Catalyst Pharmaceutical CPRX Stock Holding History

INTECH Investment Management’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.4M	Sell	56,378 -13,069	-19%	-$311K	0.01%	856
2025 Q4	$1.62M	Buy	69,447 +15,034	+28%	+$335K	0.01%	855
2025 Q3	$1.07M	Sell	54,413 -46,656	-46%	-$960K	0.01%	1123
2025 Q2	$2.19M	Buy	101,069 +30,982	+44%	+$731K	0.02%	710
2025 Q1	$1.7M	Buy	70,087 +4,261	+6%	+$96K	0.02%	859
2024 Q4	$1.37M	Buy	65,826 +33,431	+103%	+$718K	0.01%	934
2024 Q3	$644K	Buy	+32,395	New	+$601K	0.01%	1082

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

INTECH Investment Management's CPRX Position: Q1 2026 in Review

INTECH Investment Management reduced its Catalyst Pharmaceutical (CPRX) stake by 19% in Q1 2026, selling an estimated $311K and leaving 56,378 shares worth $1.4M. The position accounts for 0.01% of the portfolio, ranked #856.

INTECH Investment Management first reported a position in CPRX in Q3 2024 and has held it in 7 quarters since. The position peaked at $2.19M in Q2 2025. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

INTECH Investment Management held 56,378 shares of Catalyst Pharmaceutical worth $1.4M as of Q1 2026.
INTECH Investment Management sold 13,069 Catalyst Pharmaceutical shares in Q1 2026, an estimated $311K.
Catalyst Pharmaceutical made up 0.01% of INTECH Investment Management's portfolio in Q1 2026, its #856 holding.
INTECH Investment Management first reported a position in Catalyst Pharmaceutical in Q3 2024 and has held it in 7 quarters since.
INTECH Investment Management's Catalyst Pharmaceutical position peaked at $2.19M in Q2 2025.
380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on INTECH Investment Management's 13F filing for Q1 2026, filed 8 May 2026.